Cue Biopharma CFO Resignation and Board Appointment

Cue Biopharma ( (CUE) ) has shared an update.

On June 4, 2025, Cue Biopharma, Inc. appointed Jill Broadfoot to its board of directors, where she will serve as Chair of the Audit Committee. Additionally, the company’s stockholders approved the 2025 Stock Incentive Plan during the annual meeting. On the same day, Kerri-Ann Millar announced her resignation as Chief Financial Officer, effective June 13, 2025, with CEO Daniel R. Passeri stepping in as interim CFO. Furthermore, the company filed a Certificate of Amendment to increase its authorized shares of capital and common stock, reflecting strategic growth initiatives.

The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Spark’s Take on CUE Stock

According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.

Cue Biopharma’s overall stock score is driven primarily by its poor financial performance and valuation. The company is facing significant financial challenges with negative profitability and cash flow issues. Additionally, technical analysis indicates bearish signals, with the stock price below key moving averages and low momentum. The absence of a positive valuation further impacts the score.

To see Spark’s full report on CUE stock, click here.

More about Cue Biopharma

Average Trading Volume: 165,464

Technical Sentiment Signal: Sell

Current Market Cap: $48.3M

Find detailed analytics on CUE stock on TipRanks’ Stock Analysis page.